Deal covers identification of biomarkers of response to SuppreMol’s lead candidate SM101 SuppreMol is teaming up with Protagen to identify biomarkers of response to SuppreMol’s clinical-stage systemic ...
SuppreMol GmbH / SuppreMol announces presentation of clinical data for its lead product SM101 at the 54th ASH Annual Meeting . Processed and transmitted by Thomson Reuters ONE. The issuer is solely ...
BMBF grant will facilitate Phase I trials of SM101 in SLE and preclinical studies in COPD. SuppreMol has been awarded €1.6 million ($2.1 million) in research funding from the German Federal Ministry ...
SuppreMol GmbH, a privately held biopharmaceutical company developing innovative therapeutics for the treatment of autoimmune diseases and allergies, and Protagen AG, a specialist in in-vitro ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results